BFS-Calcium Folinate
Folinic acid (as calcium folinate) 50 mg/5 ml
Diminish the toxicity and counteract the action of folic acid antagonists
BFS-Adenosin 2ml
Adenosine
Rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardia
BFS- Paracetamol
Paracetamol 1000mg/10ml
Indicated for the short-term treatment of moderate pain and short-term of fever
Atropine BFS
Atropine sulfate
Inhibition the effects of the parasympathetic nervous system
Folinic acid (as calcium folinate) 50 mg/5 ml
Solution for injection
Indicated for:
- Diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children
- In combination with 5-fluorouracil in cytotoxic therapy.
Calcium Folinate Rescue in methotrexate therapy:
Dosage and duration of use of Calcium folinate primarily depend on the type and dosage of methotrexate therapy, the occurrence of toxicity symptoms, and the individual excretion capacity for methotrexate. As a rule, the first dose of Calcium folinate is 15 mg (6-12 mg/m²) to be given 12-24 hours (24 hours at the latest) after the beginning of the methotrexate infusion. The same dose is given every 6 hours throughout a period of 72 hours. After several parenteral doses treatment can be switched over to the oral form.
In combination with 5-fluorouracil in cytotoxic therapy:
Bimonthly regimen:
Calcium folinate 200mg/m² by intravenous infusion over two hours, followed by an intravenous bolus of 400 mg/m² of 5-Fluorouracil and a 22-hour intravenous infusion of 5-Fluorouracil (600 mg/m²) for 2 consecutive days, every 2 weeks on days 1 and 2.
Weekly regimen:
Calcium folinate 20mg/m² by intravenous bolus. injection or 200 to 500 mg/m² intravenous. infusion over a period of 2 hours, plus 500 mg/m² 5-fluorouracil as an intravenous bolus injection in the middle, or at the end, of the calcium folinate infusion.
Monthly regimen:
Calcium folinate 20 mg/m² by bolus i.v. injection or 200 to 500 mg/m² as i.v. infusion over a period of 2 hours immediately followed by 425 or 370 mg/m² 5-fluorouracil as an intravenous bolus injection over five consecutive days.
For the use of calcium folinate in combination with 5-fluorouracil, modification of the 5-fluorouacil dosage and the treatment-free interval may be necessary depending on patient condition, clinical response and dose limiting toxicity as stated in the product information of 5-fluorouracil. A reduction of calcium folinate dosage is not required.
Adenosine 3mg/ml
Solution for injection
Rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory by-pass tracts (Wolff-Parkinson-White Syndrome).
Paediatric population
Rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardia in children aged 0 to 18 years.
Diagnostic indications
Aid to diagnosis of broad or narrow complex supraventricular tachycardias. Although adenosin will not convert atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of AV conduction helps diagnosis of atrial activity.
Sensitisation of intra-cavitary electrophysiological investigations.
It should be administered by rapid IV bolus injection according to the ascending dosage schedule below. To be certain the solution reaches the systemic circulation administer either directly into a vein or into an IV line. If given into an IV line it should be injected as proximally as possible, and followed by a rapid saline flush.
BFS-Adenosin should only be used when facilities exist for cardiac monitoring. Patients who develop high-level AV block at a particular dose should not be given further dosage increments.
Paracetamol 1000mg/10ml
Concentrated solution for infusion
Indicated for the short-term treatment of moderate pain, especially following surgery, and for the short-term treatment of fever
Adults: Adults and adolescents weighing under 50 kg: the recommended dosage of acetaminophen
injection is 15 mg/kg every 6 hours or 12.5 mg/kg every 4 hours, with a maximum single
dose of acetaminophen injection of 15 mg/kg, a minimum dosing interval of 4 hours, and a
maximum daily dose of acetaminophen of 75 mg/kg per day.
Children: Children 2 to 12 years of age: the recommended dosage of acetaminophen injection is 15
mg/kg every 6 hours or 12.5 mg/kg every 4 hours, with a maximum single dose of acetaminophen injection of 15 mg/kg, a minimum dosing interval of 4 hours, and a maximum daily dose of acetaminophen of 75 mg/kg per day.
Atropine sulfate 0.25mg/ml
Solution for injection
Atropine and anti-muscarin drugs are used to inhibit the effects of the parasympathetic nervous system in many cases:
- Gastrointestinal disorders.
- Gastric or duodenal ulcer: Inhibits the ability of gastric acid secretion.
- Irritable bowel syndrome: Decreased bowel spasm, reduces fluid secretion.
Atropine Injection 0.25mg/ml may be administered undiluted by IV (intravenous) injection.
In adults: It is recommended that three (3) doses be available for use in each person at risk for nerve agent or organophosphate insecticide poisoning; one (1) for mild symptoms plus two (2) more for severe symptoms as described below. No more than three (3) doses injections should be used unless the patient is under the supervision of a trained medical provider.
Different dose strengths are available depending on the recipient’s age. The following doses of atropine 0.25mg are recommnded like below:
- Adults and children weighing over 90 lbs (41 kg) or generally over 10 years of age: 2mg
- Children weighing 40 lbs to 90 lbs (18 – 41 kg) or generally 4 to 10 years of age: 1mg
- Children weighing 15 lbs to 40 lbs (7 – 18 kg) or generally 6 months to 4 years of age: 0.5mg
- Infants weighing less than 15 lbs (7 kg) or generally less than 6 months of age: 0.25mg
ADRENALINE BFS
Adrenaline (as Adrenaline tartrate) 1mg/ml
Treat of cardiovascular arrest, anaphylactic shock and cardiocirculatory distress
WATER FOR INJECTION
Water for injection
Used as a vehicle for dilution and reconstitution of medicinal products
ONDANSETRON-BFS
Ondansetron (as Ondansetron HCl Dihydrate
Prevention of nausea and vomiting associated with chemotherapy
KAMA-BFS
Magnesium aspartate/Potassium aspartate
Treatment of heart failure, myocardial infarction, cardiac arrthmias
Adrenaline (as Adrenaline tartrate) 1mg/ml
Ampoule 1ml, 5ml
Solution for injection
Treat of cardiovascular arrest, anaphylactic shock and cardiocirculatory distress with states of anaphylactic, hemorrhagic, traumatic shock,
infectious or secondary to cardiac surgery
Posology
Severe hypersensitivity reactions, anaphylactic shock
IM Injection:
Adults: The usual dose is 500 micrograms (0.5ml of adrenaline 1/1000). If necessary, this dose may be repeated several times at 5-minute intervals according to blood pressure, pulse and respiratory function.
Half doses of adrenaline may be safer for patients who are taking amitriptyline, imipramine or a beta blocker.
Paediatric population
The following doses of adrenaline 1/1,000 are recommended:
Age | Dose |
Over 12 years | 0.5 mg IM (0.5ml 1:1000 solution) |
6 - 12 years | 0.3 mg IM (0.3ml 1:1000 solution) |
6 months - 6 years | 0.15 mg IM (0.15ml 1:1000 solution) |
Under 6 months | 0.01mg/kg IM (0.01ml/kg 1:1000 solution) |
If necessary, these doses may be repeated at 5-15 -minute intervals according to blood pressure, pulse and respiratory function.
Elderly
The dosage is the same as for younger adults but particular caution is required when administering adrenaline to elderly patients (see section 4.4).
Renal impairment
Adrenaline should be used with caution in patients with severe renal impairment (see section 4.4).
Method of Administration
Adrenaline Injection BP. 1/1000 (1mg/ml) may be administered undiluted by S.C. or IM injection. In the shocked patient, the intramuscular route is recommended as absorption from the intramuscular site is more rapid and reliable than from the subcutaneous site.
A small volume syringe should be used.
Water for injection
Ampoule 5ml
Solvent for injection
Used as a vehicle for dilution and reconstitution of suitable medicinal products for parenteral administration.
Posology
The dosage administered will be dictated by the nature of the additive used. The administration rate will be dependent upon the dose regimen of the prescribed drug.
Following suitable admixture of prescribed additives, the dosage is usually dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.
The solution should only be used if it is clear without visible particles.
Method of administration
For parenteral use.
The directions for use will be dependent upon the appropriate medicinal product to which this solvent is added, which will dictate the appropriate volumes as well as administration route.
Ondansetron (as Ondansetron HCl Dihydrate): 8mg/4ml
Solution for injection
Prevention Of Nausea And Vomiting Associated With Initial And Repeat Courses Of Emetogenic
Cancer Chemotherapy (It is approved for patients aged 6 months and older)
Prevention Of Postoperative Nausea And/Or Vomiting (It is approved for patients aged 1 month and older)
Each ampoule of 10 ml contains:
Magnesium aspartate: 400 mg
Potassium aspartate: 452 mg
Solution for injection
- Adjuvant treatment of chronic heart disease (heart failure, myocardial infarction), cardiac arrhythmias, primarily ventricular arrhythmias.
- To improve tolerance of cardiac glycosides.
- A single dose of 1-2 ampoules. To prepare the infusion solution contents of the ampoules are dissolved in 5% glucose solution (50-100 ml).
- This dose may be repeated after 4 to 6 hours if necessary.
- Suitable for combination treatment.
HEPAPHAGHEN 10-BFS
Glycyrrhizinate ammonium/ Glycine/ L-cysteine hydrochloride monohydrate
Treatment and prevention chronic hepatitis
HEPAPHAGEN-BFS
Glycyrrhizinate ammonium/ Glycine/ L-cysteine hydrochloride monohydrate
Treatment and prevention chronic hepatitis
BFS-GALANTAMINE 5mg
Galantamine hydrobromide
Treat mild to moderate confusion (dementia)
ZENTANIL
Acetyl leucin
Symptomatic treatment of the vertiginous crisis
Each ml contains:
Glycyrrhizine 2mg (as Glycyrrhizinate ammonium)
Glycine 20mg
L-cysteine hydrochloride 1mg (as L-cysteine hydrochloride monohydrate)
Ampoule 10ml
Solution for injection
- Used in the treatment of chronic hepatitis. Prevent the development of hepatocellular carcinoma in patients with chronic hepatitis C.
- Eczema or dermatitis, urticaria, pruritus, rash due to drug or poisoning, tingling disease or stomatitis.
Drugs used intravenously. Use as directed by doctors.
Adults:
Usual dose: Inject 5-20ml once a day. The dosage may be adjusted depending on the age and symptoms of the patient.
Patients with hepatitis:
Inject or infuse 40-60 ml once a day. The dosage may be adjusted depending on the age and symptoms of the patient. The maximum daily dose should not exceed 100ml / day.
Pediatric patients:
There are no adequate and well-controlled studies on pediatric patients. Not recommended for this group.
Elderly patients:
Elderly patients tend to have hypokalemia. Therefore, the patient's drug use should be closely monitored.
Use for pregnant and lactating women:
There are no adequate and well-controlled studies on pediatric patients. Do not use for these objects.
Each ml contains:
Glycyrrhizine 2mg (as Glycyrrhizinate ammonium)
Glycine 20mg
L-cysteine hydrochloride 1mg (as L-cysteine hydrochloride monohydrate)
Ampoule 5ml
Solution for injection
- Used in the treatment of chronic hepatitis. Prevent the development of hepatocellular carcinoma in patients with chronic hepatitis C.
- Eczema or dermatitis, urticaria, pruritus, rash due to drug or poisoning, tingling disease or stomatitis.
Drugs used intravenously. Use as directed by doctors.
Adults:
Usual dose: Inject 5-20ml once a day. The dosage may be adjusted depending on the age and symptoms of the patient.
Patients with hepatitis:
Inject or infuse 40-60 ml once a day. The dosage may be adjusted depending on the age and symptoms of the patient. The maximum daily dose should not exceed 100ml / day.
Pediatric patients:
There are no adequate and well-controlled studies on pediatric patients. Not recommended for this group.
Elderly patients:
Elderly patients tend to have hypokalemia. Therefore, the patient's drug use should be closely monitored.
Use for pregnant and lactating women:
There are no adequate and well-controlled studies on pediatric patients. Do not use for these objects.
Galantamine hydrobromide 5mg/5ml
Injection solution
Poliomyelitis – immediately after the fall of temperature, as well as in the recuperative and residual period; neuritis, radiculitis, radiculoneurities, polyneuritis, spastic pareses and paralyses and other sequelae of lesions of vascular, inflammatory, toxic and traumatic origin. As antidote, in morphine poisoning; in ophthalmology – mainly pronary glaucoma; secondary glaucoma
FS-Galantamine 5 mg is only used under the supervision of a doctor.
Dosage and duration of treatment depend on the type of disease and the severity of the disease.
The drug is administered by subcutaneous, intramuscular or intravenous.
In the treatment of neuropathy:
Adults
The initial dose is usually 2.5 mg
Can gradually increase the dose to achieve optimal effect.
The largest single dose for adults is 10 mg and the maximum daily dose is 20 mg, divided into 2 - 3 equal doses.
Children
Subcutaneous doses in children are determined by a doctor, depending on age and weight.
In anesthesia, surgery and detoxification
Adults
Intravenous injection at a dose of 10-20 mg daily.
In the treatment paralytic ileus and bladder paralysis after surgery, use 2-3 times a day, the dose prescribed by the doctor.
Children
Subcutaneous doses in children are determined by a doctor, depending on age and weight.
In physiotherapy
In physiotherapy, BFS-Galantamine 5 mg is used via ion transfer electrolyte (iontophoresis) at a dose of 2.5 - 5 mg (with an electric current of 1 - 2 mA) for 10 minutes with a time interval of 10-15 days.
Acetyl leucin 1g/10ml
Solution for injection
Symptomatic treatment of the dizzy crisis.
1.5 to 2 g per day, i.e. 3 to 4 tablets in two doses, morning and evening. The treatment duration varies according to clinical progression (from 10 days to 5 or 6 weeks). At the start of treatment, or in the event of failure, the dosage may be safely increased up to 3g or even 4g per day.
BFS-Calcium Folinate
Folinic acid (as calcium folinate) 50 mg/5 ml
Diminish the toxicity and counteract the action of folic acid antagonists
BFS-Adenosin 2ml
Adenosine
Rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardia
Folinic acid (as calcium folinate) 50 mg/5 ml
Solution for injection
Indicated for:
- Diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children
- In combination with 5-fluorouracil in cytotoxic therapy.
Calcium Folinate Rescue in methotrexate therapy:
Dosage and duration of use of Calcium folinate primarily depend on the type and dosage of methotrexate therapy, the occurrence of toxicity symptoms, and the individual excretion capacity for methotrexate. As a rule, the first dose of Calcium folinate is 15 mg (6-12 mg/m²) to be given 12-24 hours (24 hours at the latest) after the beginning of the methotrexate infusion. The same dose is given every 6 hours throughout a period of 72 hours. After several parenteral doses treatment can be switched over to the oral form.
In combination with 5-fluorouracil in cytotoxic therapy:
Bimonthly regimen:
Calcium folinate 200mg/m² by intravenous infusion over two hours, followed by an intravenous bolus of 400 mg/m² of 5-Fluorouracil and a 22-hour intravenous infusion of 5-Fluorouracil (600 mg/m²) for 2 consecutive days, every 2 weeks on days 1 and 2.
Weekly regimen:
Calcium folinate 20mg/m² by intravenous bolus. injection or 200 to 500 mg/m² intravenous. infusion over a period of 2 hours, plus 500 mg/m² 5-fluorouracil as an intravenous bolus injection in the middle, or at the end, of the calcium folinate infusion.
Monthly regimen:
Calcium folinate 20 mg/m² by bolus i.v. injection or 200 to 500 mg/m² as i.v. infusion over a period of 2 hours immediately followed by 425 or 370 mg/m² 5-fluorouracil as an intravenous bolus injection over five consecutive days.
For the use of calcium folinate in combination with 5-fluorouracil, modification of the 5-fluorouacil dosage and the treatment-free interval may be necessary depending on patient condition, clinical response and dose limiting toxicity as stated in the product information of 5-fluorouracil. A reduction of calcium folinate dosage is not required.
Adenosine 3mg/ml
Solution for injection
Rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory by-pass tracts (Wolff-Parkinson-White Syndrome).
Paediatric population
Rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardia in children aged 0 to 18 years.
Diagnostic indications
Aid to diagnosis of broad or narrow complex supraventricular tachycardias. Although adenosin will not convert atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of AV conduction helps diagnosis of atrial activity.
Sensitisation of intra-cavitary electrophysiological investigations.
It should be administered by rapid IV bolus injection according to the ascending dosage schedule below. To be certain the solution reaches the systemic circulation administer either directly into a vein or into an IV line. If given into an IV line it should be injected as proximally as possible, and followed by a rapid saline flush.
BFS-Adenosin should only be used when facilities exist for cardiac monitoring. Patients who develop high-level AV block at a particular dose should not be given further dosage increments.
BFS- Paracetamol
Paracetamol 1000mg/10ml
Indicated for the short-term treatment of moderate pain and short-term of fever
Atropine BFS
Atropine sulfate
Inhibition the effects of the parasympathetic nervous system
Paracetamol 1000mg/10ml
Concentrated solution for infusion
Indicated for the short-term treatment of moderate pain, especially following surgery, and for the short-term treatment of fever
Adults: Adults and adolescents weighing under 50 kg: the recommended dosage of acetaminophen
injection is 15 mg/kg every 6 hours or 12.5 mg/kg every 4 hours, with a maximum single
dose of acetaminophen injection of 15 mg/kg, a minimum dosing interval of 4 hours, and a
maximum daily dose of acetaminophen of 75 mg/kg per day.
Children: Children 2 to 12 years of age: the recommended dosage of acetaminophen injection is 15
mg/kg every 6 hours or 12.5 mg/kg every 4 hours, with a maximum single dose of acetaminophen injection of 15 mg/kg, a minimum dosing interval of 4 hours, and a maximum daily dose of acetaminophen of 75 mg/kg per day.
Atropine sulfate 0.25mg/ml
Solution for injection
Atropine and anti-muscarin drugs are used to inhibit the effects of the parasympathetic nervous system in many cases:
- Gastrointestinal disorders.
- Gastric or duodenal ulcer: Inhibits the ability of gastric acid secretion.
- Irritable bowel syndrome: Decreased bowel spasm, reduces fluid secretion.
Atropine Injection 0.25mg/ml may be administered undiluted by IV (intravenous) injection.
In adults: It is recommended that three (3) doses be available for use in each person at risk for nerve agent or organophosphate insecticide poisoning; one (1) for mild symptoms plus two (2) more for severe symptoms as described below. No more than three (3) doses injections should be used unless the patient is under the supervision of a trained medical provider.
Different dose strengths are available depending on the recipient’s age. The following doses of atropine 0.25mg are recommnded like below:
- Adults and children weighing over 90 lbs (41 kg) or generally over 10 years of age: 2mg
- Children weighing 40 lbs to 90 lbs (18 – 41 kg) or generally 4 to 10 years of age: 1mg
- Children weighing 15 lbs to 40 lbs (7 – 18 kg) or generally 6 months to 4 years of age: 0.5mg
- Infants weighing less than 15 lbs (7 kg) or generally less than 6 months of age: 0.25mg
ADRENALINE BFS
Adrenaline (as Adrenaline tartrate) 1mg/ml
Treat of cardiovascular arrest, anaphylactic shock and cardiocirculatory distress
WATER FOR INJECTION
Water for injection
Used as a vehicle for dilution and reconstitution of medicinal products
Adrenaline (as Adrenaline tartrate) 1mg/ml
Ampoule 1ml, 5ml
Solution for injection
Treat of cardiovascular arrest, anaphylactic shock and cardiocirculatory distress with states of anaphylactic, hemorrhagic, traumatic shock,
infectious or secondary to cardiac surgery
Posology
Severe hypersensitivity reactions, anaphylactic shock
IM Injection:
Adults: The usual dose is 500 micrograms (0.5ml of adrenaline 1/1000). If necessary, this dose may be repeated several times at 5-minute intervals according to blood pressure, pulse and respiratory function.
Half doses of adrenaline may be safer for patients who are taking amitriptyline, imipramine or a beta blocker.
Paediatric population
The following doses of adrenaline 1/1,000 are recommended:
Age | Dose |
Over 12 years | 0.5 mg IM (0.5ml 1:1000 solution) |
6 - 12 years | 0.3 mg IM (0.3ml 1:1000 solution) |
6 months - 6 years | 0.15 mg IM (0.15ml 1:1000 solution) |
Under 6 months | 0.01mg/kg IM (0.01ml/kg 1:1000 solution) |
If necessary, these doses may be repeated at 5-15 -minute intervals according to blood pressure, pulse and respiratory function.
Elderly
The dosage is the same as for younger adults but particular caution is required when administering adrenaline to elderly patients (see section 4.4).
Renal impairment
Adrenaline should be used with caution in patients with severe renal impairment (see section 4.4).
Method of Administration
Adrenaline Injection BP. 1/1000 (1mg/ml) may be administered undiluted by S.C. or IM injection. In the shocked patient, the intramuscular route is recommended as absorption from the intramuscular site is more rapid and reliable than from the subcutaneous site.
A small volume syringe should be used.
Water for injection
Ampoule 5ml
Solvent for injection
Used as a vehicle for dilution and reconstitution of suitable medicinal products for parenteral administration.
Posology
The dosage administered will be dictated by the nature of the additive used. The administration rate will be dependent upon the dose regimen of the prescribed drug.
Following suitable admixture of prescribed additives, the dosage is usually dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.
The solution should only be used if it is clear without visible particles.
Method of administration
For parenteral use.
The directions for use will be dependent upon the appropriate medicinal product to which this solvent is added, which will dictate the appropriate volumes as well as administration route.
ONDANSETRON-BFS
Ondansetron (as Ondansetron HCl Dihydrate
Prevention of nausea and vomiting associated with chemotherapy
KAMA-BFS
Magnesium aspartate/Potassium aspartate
Treatment of heart failure, myocardial infarction, cardiac arrthmias
Ondansetron (as Ondansetron HCl Dihydrate): 8mg/4ml
Solution for injection
Prevention Of Nausea And Vomiting Associated With Initial And Repeat Courses Of Emetogenic
Cancer Chemotherapy (It is approved for patients aged 6 months and older)
Prevention Of Postoperative Nausea And/Or Vomiting (It is approved for patients aged 1 month and older)
Each ampoule of 10 ml contains:
Magnesium aspartate: 400 mg
Potassium aspartate: 452 mg
Solution for injection
- Adjuvant treatment of chronic heart disease (heart failure, myocardial infarction), cardiac arrhythmias, primarily ventricular arrhythmias.
- To improve tolerance of cardiac glycosides.
- A single dose of 1-2 ampoules. To prepare the infusion solution contents of the ampoules are dissolved in 5% glucose solution (50-100 ml).
- This dose may be repeated after 4 to 6 hours if necessary.
- Suitable for combination treatment.
HEPAPHAGHEN 10-BFS
Glycyrrhizinate ammonium/ Glycine/ L-cysteine hydrochloride monohydrate
Treatment and prevention chronic hepatitis
HEPAPHAGEN-BFS
Glycyrrhizinate ammonium/ Glycine/ L-cysteine hydrochloride monohydrate
Treatment and prevention chronic hepatitis
Each ml contains:
Glycyrrhizine 2mg (as Glycyrrhizinate ammonium)
Glycine 20mg
L-cysteine hydrochloride 1mg (as L-cysteine hydrochloride monohydrate)
Ampoule 10ml
Solution for injection
- Used in the treatment of chronic hepatitis. Prevent the development of hepatocellular carcinoma in patients with chronic hepatitis C.
- Eczema or dermatitis, urticaria, pruritus, rash due to drug or poisoning, tingling disease or stomatitis.
Drugs used intravenously. Use as directed by doctors.
Adults:
Usual dose: Inject 5-20ml once a day. The dosage may be adjusted depending on the age and symptoms of the patient.
Patients with hepatitis:
Inject or infuse 40-60 ml once a day. The dosage may be adjusted depending on the age and symptoms of the patient. The maximum daily dose should not exceed 100ml / day.
Pediatric patients:
There are no adequate and well-controlled studies on pediatric patients. Not recommended for this group.
Elderly patients:
Elderly patients tend to have hypokalemia. Therefore, the patient's drug use should be closely monitored.
Use for pregnant and lactating women:
There are no adequate and well-controlled studies on pediatric patients. Do not use for these objects.
Each ml contains:
Glycyrrhizine 2mg (as Glycyrrhizinate ammonium)
Glycine 20mg
L-cysteine hydrochloride 1mg (as L-cysteine hydrochloride monohydrate)
Ampoule 5ml
Solution for injection
- Used in the treatment of chronic hepatitis. Prevent the development of hepatocellular carcinoma in patients with chronic hepatitis C.
- Eczema or dermatitis, urticaria, pruritus, rash due to drug or poisoning, tingling disease or stomatitis.
Drugs used intravenously. Use as directed by doctors.
Adults:
Usual dose: Inject 5-20ml once a day. The dosage may be adjusted depending on the age and symptoms of the patient.
Patients with hepatitis:
Inject or infuse 40-60 ml once a day. The dosage may be adjusted depending on the age and symptoms of the patient. The maximum daily dose should not exceed 100ml / day.
Pediatric patients:
There are no adequate and well-controlled studies on pediatric patients. Not recommended for this group.
Elderly patients:
Elderly patients tend to have hypokalemia. Therefore, the patient's drug use should be closely monitored.
Use for pregnant and lactating women:
There are no adequate and well-controlled studies on pediatric patients. Do not use for these objects.
BFS-GALANTAMINE 5mg
Galantamine hydrobromide
Treat mild to moderate confusion (dementia)
ZENTANIL
Acetyl leucin
Symptomatic treatment of the vertiginous crisis
Galantamine hydrobromide 5mg/5ml
Injection solution
Poliomyelitis – immediately after the fall of temperature, as well as in the recuperative and residual period; neuritis, radiculitis, radiculoneurities, polyneuritis, spastic pareses and paralyses and other sequelae of lesions of vascular, inflammatory, toxic and traumatic origin. As antidote, in morphine poisoning; in ophthalmology – mainly pronary glaucoma; secondary glaucoma
FS-Galantamine 5 mg is only used under the supervision of a doctor.
Dosage and duration of treatment depend on the type of disease and the severity of the disease.
The drug is administered by subcutaneous, intramuscular or intravenous.
In the treatment of neuropathy:
Adults
The initial dose is usually 2.5 mg
Can gradually increase the dose to achieve optimal effect.
The largest single dose for adults is 10 mg and the maximum daily dose is 20 mg, divided into 2 - 3 equal doses.
Children
Subcutaneous doses in children are determined by a doctor, depending on age and weight.
In anesthesia, surgery and detoxification
Adults
Intravenous injection at a dose of 10-20 mg daily.
In the treatment paralytic ileus and bladder paralysis after surgery, use 2-3 times a day, the dose prescribed by the doctor.
Children
Subcutaneous doses in children are determined by a doctor, depending on age and weight.
In physiotherapy
In physiotherapy, BFS-Galantamine 5 mg is used via ion transfer electrolyte (iontophoresis) at a dose of 2.5 - 5 mg (with an electric current of 1 - 2 mA) for 10 minutes with a time interval of 10-15 days.
Acetyl leucin 1g/10ml
Solution for injection
Symptomatic treatment of the dizzy crisis.
1.5 to 2 g per day, i.e. 3 to 4 tablets in two doses, morning and evening. The treatment duration varies according to clinical progression (from 10 days to 5 or 6 weeks). At the start of treatment, or in the event of failure, the dosage may be safely increased up to 3g or even 4g per day.